沃森生物：签署微生态健康靶向技术独家再许可协议之修正案

Core Viewpoint - Watson Bio has signed an exclusive sublicensing agreement with Notitia Biotechnologies to expand its collaboration into the non-patient field, allowing for the development and commercialization of specific technologies in China, Hong Kong, and Macau [1] Group 1: Agreement Details - The exclusive sublicensing agreement was signed on May 23, 2025, focusing on the "patient field" initially [1] - The amendment to the agreement aims to include relevant intellectual property and proprietary technology for the non-patient field [1] Group 2: Technology and Rights - Notitia will grant Watson Bio exclusive rights to develop, manufacture, and commercialize core microbiome analysis, microbiome-targeted transplantation, and nutritional formulation technologies in mainland China, Hong Kong, and Macau [1] - These technologies are derived from an upstream licensing agreement between Notitia and Rutgers University in New Jersey [1]